1. Home
  2. ACRS vs HDL Comparison

ACRS vs HDL Comparison

Compare ACRS & HDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$6.28

Market Cap

868.5M

Sector

Health Care

ML Signal

HOLD

HDL

SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

N/A

Current Price

$14.24

Market Cap

723.1M

ML Signal

N/A

Company Overview

Basic Information
Metric
ACRS
HDL
Founded
2012
2016
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
868.5M
723.1M
IPO Year
2015
2023

Fundamental Metrics

Financial Performance
Metric
ACRS
HDL
Price
$6.28
$14.24
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$10.20
N/A
AVG Volume (30 Days)
1.9M
858.0
Earning Date
05-07-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
69.01
N/A
EPS
N/A
N/A
Revenue
$1,683,000.00
N/A
Revenue This Year
N/A
$14.73
Revenue Next Year
$4.24
$12.94
P/E Ratio
N/A
$55.56
Revenue Growth
N/A
N/A
52 Week Low
$1.74
$12.00
52 Week High
$6.52
$21.21

Technical Indicators

Market Signals
Indicator
ACRS
HDL
Relative Strength Index (RSI) 61.76 60.45
Support Level $4.13 $13.07
Resistance Level $6.52 $15.40
Average True Range (ATR) 0.36 0.12
MACD 0.03 0.13
Stochastic Oscillator 83.72 100.00

Price Performance

Historical Comparison
ACRS
HDL

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

Super Hi International Holding Ltd is an investment holding company, and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.

Share on Social Networks: